NEUROONE MEDICAL TECHNOLOGIES Corp: directors' dealings · United States · SEC (Form 4)

About NEUROONE MEDICAL TECHNOLOGIES Corp

NeuroOne Medical Technologies Corporation (ticker: NMTC) is a U.S.-based medical device company listed on the Nasdaq market in the United States. The company focuses on neurotechnology solutions designed to improve the surgical diagnosis and treatment of neurological disorders. Its business sits at the intersection of neurosurgery, electrophysiology, and minimally invasive ablation therapy, which gives it a specialized niche position within the broader medtech landscape. NeuroOne is headquartered in Eden Prairie, Minnesota, a well-established U.S. medical-technology cluster. Although the corporate history traces back to 2009, the company’s current strategic focus was reset after the 2017 acquisition of NeuroOne, Inc., which effectively transformed the business into a dedicated neurological-medtech platform. NeuroOne’s commercial portfolio is built around a minimally invasive, high-precision technology platform with four FDA-cleared product families under 510(k): Evo Cortical electrodes for surface-brain recording and stimulation, Evo sEEG electrodes for subsurface brain monitoring and stimulation, the OneRF ablation system for radiofrequency lesions in the brain, and the OneRF TN system for pain-related and certain cranial-nerve applications. In operational terms, this gives the company exposure to two adjacent clinical markets: neurological monitoring/diagnostics and therapeutic neuroablation. The strategy is to address medical needs where precision and reduced invasiveness are important, while competing against better-capitalized and more established players in the neuromedical device sector. From a competitive standpoint, NeuroOne aims to differentiate itself through product design rather than scale. Its value proposition is centered on minimally invasive procedures, high-definition signal capture, and targeted lesioning capability. A key commercialization lever is its distribution agreement with Zimmer, which grants Zimmer exclusive distribution rights for certain OneRF products. For a small-cap medtech company, that type of partnership is important because it can broaden market access, support physician adoption, and reduce the burden of building a large direct sales infrastructure from scratch. Recent developments point to improving commercial traction. In 2025, NeuroOne highlighted strong product revenue growth and reported progress driven by its OneRF platform. It also announced the first successful treatments of facial pain patients using its OneRF trigeminal nerve ablation system. In early 2026, management said momentum had continued across target markets, suggesting that the company is transitioning from a pure development story toward early commercialization. That said, investors should still view NMTC as a high-risk growth story: the company remains exposed to regulatory execution, reimbursement uncertainty, funding needs, and continued Nasdaq listing compliance. For international equity investors, NeuroOne is best characterized as a niche U.S. Nasdaq-listed medtech platform with differentiated technology and still-emerging commercial scale.